Antigen binding molecules and methods of use thereof
AssigneeKite Pharma, Inc.
InventorsJed Wiltzius, Stuart Sievers, Arianne Perez Garcia
Life of this patent
Estimating the term…
Abstract
Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GSTSGSGKPGSGEGSTKG (SEQ ID NO: 1), GSGKPGSGEG (SEQ ID NO: 2), GKPGSGEG (SEQ ID NO: 3), SGKPGSGE (SEQ ID NO: 499) and KPGSG (SEQ ID NO: 500) are provided. The antigen binding molecules can be used in the methods provided herein.
Claims20
An isolated antigen binding molecule that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GSTSGSGKPGSGEGSTKG (SEQ ID NO:
- 1), GSGKPGSGEG (SEQ ID NO:
- 2), GKPGSGEG (SEQ ID NO:
- 3), SGKPGSGE (SEQ ID NO:
- 499), and KPGSG (SEQ ID NO:
- 500), wherein the antigen binding molecule comprises
- (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 7;
- (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 8;
- (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 9;
- (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 13;
- (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 14;
- and
- (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 15.
An isolated antigen binding molecule that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GSTSGSGKPGSGEGSTKG (SEQ ID NO:
- 1), GSGKPGSGEG (SEQ ID NO:
- 2), GKPGSGEG (SEQ ID NO:
- 3), SGKPGSGE (SEQ ID NO:
- 499), and KPGSG (SEQ ID NO:
- 500), wherein the antigen binding molecule comprises:
- (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 19;
- (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 20;
- (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 21;
- (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 25;
- (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 26;
- and
- (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 27.
Dependencies are inferred from the claim text.